CytoMed Therapeutics (NASDAQ: GDTC) director discloses holding 4,000 Ordinary Shares

Rhea-AI Filing Summary

CytoMed Therapeutics Ltd director Toh Keng Kiat has reported initial share ownership in the company. The filing shows direct beneficial ownership of 4,000 Ordinary Shares with no par value per share. This is a routine disclosure of existing holdings and does not reflect a new purchase or sale.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Toh Keng Kiat

Role null

Type	Security	Shares	Price	Value
holding	Ordinary Shares, no par value per share	--	--	--

Holdings After Transaction: Ordinary Shares, no par value per share — 4,000 shares (Direct, null)

Footnotes (1)

Key Figures

Ordinary Shares owned: 4,000 shares Buy transactions in this filing: 0 transactions Sell transactions in this filing: 0 transactions +1 more

4 metrics

Ordinary Shares owned 4,000 shares Direct beneficial ownership reported in initial statement

Buy transactions in this filing 0 transactions transactionSummary buyCount

Sell transactions in this filing 0 transactions transactionSummary sellCount

Holding entries reported 1 entry transactionSummary holdingEntries

Key Terms

Ordinary Shares, no par value per share, beneficial ownership, direct ownership, initial ownership statement

4 terms

Ordinary Shares, no par value per share financial

"security_title: Ordinary Shares, no par value per share"

beneficial ownership financial

"This is an initial statement of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

direct ownership financial

"The filing labels this as direct ownership"

initial ownership statement regulatory

"files an initial ownership statement, disclosing direct beneficial ownership"

Understanding Insider Trading Forms →

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Toh Keng Kiat

(Last) (First) (Middle)

C/O CYTOMED THERAPEUTICS LIMITED

1 COMMONWEALTH LANE #08-22

(Street)

SINGAPORE 149544

(City) (State) (Zip)

SINGAPORE

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
03/18/2026

3. Issuer Name and Ticker or Trading Symbol
CytoMed Therapeutics Ltd [ GDTC ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Ordinary Shares, no par value per share	4,000	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Keng Kiat Toh	05/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)

FAQ

What does CytoMed Therapeutics (GDTC) director Toh Keng Kiat report in this Form 3?

The director reports holding 4,000 Ordinary Shares of CytoMed Therapeutics Ltd. This is an initial statement of beneficial ownership, showing his existing direct stake rather than a new transaction in the company’s stock.

How many CytoMed Therapeutics (GDTC) shares does Toh Keng Kiat directly own?

He directly owns 4,000 Ordinary Shares of CytoMed Therapeutics Ltd. The filing labels this as direct ownership, meaning the shares are held in his name rather than through an intermediary entity or indirect structure.

Does this CytoMed Therapeutics (GDTC) Form 3 show any recent insider buying or selling?

No, the entry is categorized as a holding with an unknown transaction code. It simply discloses that the director beneficially owns 4,000 Ordinary Shares, without recording a new purchase, sale, or option exercise on the reported date.

What type of security does CytoMed Therapeutics (GDTC) disclose in this insider filing?

The filing covers Ordinary Shares with no par value per share. These are the company’s common equity securities, and the director’s 4,000-share position reflects his beneficial ownership of that class of stock.

Is the 4,000-share position in CytoMed Therapeutics (GDTC) held directly or indirectly?

The position is reported as directly owned, coded as “D” for direct ownership. This indicates the shares are held in the director’s own name rather than through a trust, partnership, or other indirect holding vehicle.